CRNX - Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

2024-05-23 05:45:52 ET

Summary

• Positive data released from 4 patients from phase 2 study that took Atumelnant for congenital adrenal hyperplasia, showing reductions in key biomarkers of A4 and 17-OHP.
• An NDA submission of Paltusotine for the treatment of patients with Acromegaly expected in the 2nd half of 2024.
• Additional results from phase 2 open-label study, using Atumelnant for patients with CAH, to be presented at ENDO Conference on June 3rd 2024 at 12:00 to 1:30 p.m. ET.
• Pending positive talks with FDA, possible initiation of phase 3 study using Paltusotine for the treatment of patients with Carcinoid Syndrome by end of 2024.

Crinetics Pharmaceuticals ( CRNX ) just released initial data from its phase 2 open-label study using its drug Atumelnant [CRN04894] for the treatment of patients with congenital adrenal hyperplasia. The data released from 4 patients was released earlier than the expected embargo date for the presentation of data, which is expected to take place at ENDO between June 1st - 4th of 2024. Despite such data being released, this doesn't mean that there isn't another catalyst relating to this program that investors can't capitalize on. That's because, as I said before, this was only the release of 4 initial patients at the time of submission. The newly released data at the ENDO 2024 medical conference is going to include data from 6 patients in cohort 1 and then other patients in cohort 2....

For further details see: